Quantcast
Tag archive for ‘chronic lymphocytic leukemia’
By Guest Author On Friday, November 19th, 2021
0 Comments

Know what is Blood Dyscrasia, It’s Symptoms, Causes and Treatment

Blood dyscrasia is generally described as a health condition where patients tend to experience an imbalance in the blood components. A person suffering from blood dyscrasia might have a smaller number of RBCs (Red More...

By Robert On Saturday, November 28th, 2015
1 Comment

Guatemala: Locally acquired Zika virus infection confirmed

Following earlier reports on Outbreak News Today of local transmission of Zika virus in El Salvador, Mexico and Paraguay, the World Health Organization reports receiving notification of a laboratory-confirmed autochthonous More...

By The Dispatch On Monday, July 28th, 2014
0 Comments

CLL drug, Imbruvica, receives FDA approval for expanded use

The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) to treat patients with chronic lymphocytic leukemia (CLL) who carry a deletion in chromosome 17 (17p deletion), which More...

By The Dispatch On Wednesday, July 23rd, 2014
1 Comment

Gilead Sciences cancer drug, Zydelig, receives FDA approval

The U.S. Food and Drug Administration today approved Zydelig (idelalisib) to treat patients with three types of blood cancers. Zydelig is being granted traditional approval to treat patients whose chronic lymphocytic More...

By Robert On Wednesday, February 12th, 2014
0 Comments

Pharmacyclics CLL drug, Imbruvica gets FDA approval

PRESS RELEASE The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for chronic lymphocytic leukemia (CLL) patients who have received at least one previous therapy. CLL is More...

By Robert On Friday, November 1st, 2013
0 Comments

Gazyva for chronic lymphocytic leukemia receives FDA approval

The U.S. Food and Drug Administration today approved Gazyva (obinutuzumab) for use in combination with chlorambucil to treat patients with previously untreated chronic lymphocytic leukemia (CLL).   CLL is a blood More...

By Robert On Thursday, September 26th, 2013
0 Comments

FDA updates ‘box warning’ for Arzerra and Rituxan to include Hepatitis B reactivation risk

The US Food and Drug Administration (FDA) announced Wednesday the approval of changes to the prescribing information of the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab) to More...


Recent Posts


DISPATCH BLOGS

Splash Page logo 300x146 Today in History